Safety of long‐term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Hepatology

• Publication date

  2015-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.27716PMID 25613809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection

  2012cited by this paper
• Patients with hematological malignancies and serological signs of prior resolved hepatitis B

  2012cited by this paper
• The role of tocilizumab in the management of rheumatoid arthritis

  2012cited by this paper
• Assessing the safety of biologic agents in patients with rheumatoid arthritis.

  2012cited by this paper
• The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review.

  2012cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Patients with hematological malignancies and serological signs of prior resolved hepatitis B.

  2012cited by this paper
• Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs

  2011cited by this paper
• Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports.

  2011cited by this paper
• The clinical implications of hepatitis B virus genotype: Recent advances

  2011cited by this paper
• Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients

  2011cited by this paper
• Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy

  2011cited by this paper
• Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

  2011cited by this paper
• Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection

  2010cited by this paper
• Possible Reactivation of Potential Hepatitis B Virus Occult Infection by Tumor Necrosis Factor-α Blocker in the Treatment of Rheumatic Diseases

  2010cited by this paper
• Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management

  2010cited by this paper
• Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti–hepatitis B core antigen positive) with rheumatic diseases

  2010cited by this paper
• Chronic hepatitis B : an update

  2010cited by this paper
• Chronic hepatitis B: Update 2009

  2009cited by this paper
• Use of Tumor Necrosis Factor-α-blocking Agents in Hepatitis B Virus-positive Patients: Reports of 3 Cases and Review of the Literature

  2009cited by this paper
• Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients

  2009cited by this paper
• Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy

  2008cited by this paper
• Statements from the Taormina expert meeting on occult hepatitis B virus infection.

  2008cited by this paper
• Occult hepatitis B virus in liver tissue of individuals without hepatic disease.

  2008influential reference
• Hepatitis B virus reactivation during therapy with etanercept in an HBsAg‐negative and anti‐HBs‐positive patient

  2008cited by this paper
• Occult hepatitis B virus infection.

  2007cited by this paper
• Efficacy of Anti‐CD20 Treatment in Patients with Rheumatoid Arthritis Resistant to a Combination of Methotrexate/Anti‐TNF Therapy

  2007cited by this paper
• Management of hepatitis B: Summary of a clinical research workshop

  2007cited by this paper
• Prophylaxis and treatment of hepatitis B in immunocompromised patients.

  2007influential reference
• Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.

  2006cited by this paper
• Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006).

  2006cited by this paper
• Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies

  2006cited by this paper
• Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

  2006cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

  2004cited by this paper
• Occult hepatitis B.

  2002cited by this paper
• Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

  2001cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• European Association for the Study of the Liver

  1971cited by this paper

• TNF‐α Inhibitors and HBV Reactivation Risk in HBsAg−/Anti‐HBc+ Patients: A Systematic Review and Meta‐Analysis

  2026cites this paper
• Infection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases.

  2026cites this paper
• Morvan syndrome with bilateral basal ganglia hyperintensities and exfoliative skin rashes in a patient with Chronic Hepatitis B: A diagnostic and therapeutic dilemma.

  2025cites this paper
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9).

  2025cites this paper
• AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals.

  2025cites this paper
• Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer

  2024cites this paper
• North American Clinical Practice Guidelines for the Medical Management of Hidradenitis Suppurativa in Special Patient Populations.

  2024cites this paper
• Risk of Hepatitis B Virus Reactivation in COVID-19 Patients Receiving Immunosuppressive Treatment: A Prospective Study

  2024cites this paper
• What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis

  2024cites this paper
• Rituximab carries high risks of hepatitis B virus reactivation in hematologic and rheumatic patients with chronic or resolved hepatitis B

  2024cites this paper
• Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy

  2024cites this paper
• Risk of hepatitis B reactivation in HBsAg−/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta‐analysis

  2023cites this paper
• HBV reactivation in HBsAg−/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs

  2023cites this paper
• The Epidemiology, Transmission, Genotypes, Replication, Serologic and Nucleic Acid Testing, Immunotolerance, and Reactivation of Hepatitis B Virus

  2023cites this paper
• HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis

  2023cites this paper
• Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study

  2023cites this paper
• HBsAg (−)/HBsAb (−)/HBeAg (−)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B‐cell lymphoma receiving rituximab based immunochemotherapy

  2023cites this paper
• Risk of infections in patients with pemphigus treated with rituximab versus azathioprine or mycophenolate mofetil: A large-scale global cohort study.

  2023cites this paper
• Hepatitis B Virus Reactivation Associated With Therapeutic Interventions

  2022cites this paper
• Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation

  2022cites this paper
• 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases

  2022cites this paper
• Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases

  2022cites this paper
• Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas

  2022cites this paper
• Meta‐analysis: hepatitis B reactivation in patients receiving biological therapy

  2022cites this paper
• Hepatitis B Virus Reactivation Associated with New Classes of Immunosuppressants and Immunomodulators: A Systematic Review, Meta-analysis, and Expert Opinion.

  2022cites this paper
• Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases

  2022cites this paper
• Anti-rheumatic Drug-induced Hepatitis B Virus Reactivation and Preventive Strategies for Hepatocellular Carcinoma.

  2022cites this paper
• Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy

  2021cites this paper
• Occult Hepatitis B Infection

  2021cites this paper
• S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)

  2021cites this paper
• Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection

  2021cites this paper
• Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment

  2021cites this paper
• Hepatitis B Virus Reactivation and Management of Patients Undergoing Immunosuppression

  2021cites this paper
• Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease

  2021cites this paper
• Tuberculin skin test conversion in patients under treatment with anti-tumor necrotizing factor alpha agents

  2020cites this paper
• Hepatitis B Virus Reactivation Potentiated by Biologics.

  2020cites this paper
• Low but Long-lasting Risk of Reversal of Seroconversion in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy.

  2020cites this paper
• Moderate Risk of Hepatitis B Virus Reactivation in HBsAg−/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis

  2020cites this paper
• Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations

  2020cites this paper
• Hepatitis B virus Reactivation in Patients Receiving Tocilizumab for Rheumatoid Arthritis: A Long‐term, Retrospective Observational Study

  2020cites this paper
• Regarding the problem of viral hepatitis reactivation in rheumatic diseases: risks and curation issues

  2020cites this paper
• Risk of hepatitis B reactivation in patients receiving anti‐tumor necrosis factor‐α therapy

  2020cites this paper
• Safety of systemic treatments for Behçet’s syndrome

  2020cites this paper
• Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?

  2020cites this paper
• [Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients].

  2019cites this paper
• Update upon the infection risk in patients receiving TNF alpha inhibitors

  2019cites this paper
• Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations

  2019cites this paper
• Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.

  2019cites this paper
• Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers

  2019cites this paper
• Safety of systemic therapy for noninfectious uveitis

  2019cites this paper
• Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics

  2019cites this paper
• Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review

  2018influential citation
• Short article: Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases

  2018cites this paper
• Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis

  2018cites this paper
• Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases.

  2018cites this paper
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).

  2018cites this paper
• Genetic polymorphism and decreased expression of HLA class II DP genes are associated with HBV reactivation in patients treated with immunomodulatory agents

  2018cites this paper
• Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance

  2018cites this paper
• Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long‐term Treatment With Tumor Necrosis Factor Antagonists

  2018cites this paper
• Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

  2018cites this paper
• Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy

  2018cites this paper
• Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease‐Modifying Antirheumatic Drugs: A Systematic Review and Meta‐Analysis

  2018cites this paper
• Recent Advances in HBV Reactivation Research

  2018cites this paper
• HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis.

  2018cites this paper
• Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease‐modifying antirheumatic drugs

  2018cites this paper
• Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs—a single-center analysis of 2054 patients

  2018cites this paper
• Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review

  2018cites this paper
• Viral infections in the biologic therapy era

  2018cites this paper
• Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

  2018cites this paper
• Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention.

  2017cites this paper
• Was nun? Elevated liver Enzymes in Patients with a Rheumatic Disease. What Comes Next?

  2017influential citation
• Reactivation of Hepatitis B Virus and Its Prevention in Patients with Rheumatic Diseases Receiving Immunosuppressive Therapy

  2017cites this paper
• Erhöhte Leberwerte bei einem Rheumapatienten. Was nun?

  2017influential citation
• Prise en charge de l’infection par le virus de l’hépatite B chez les patients atteints de polyarthrite rhumatoïde : conférence de consensus italienne

  2017cites this paper
• Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis.

  2017cites this paper
• Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study.

  2017cites this paper
• Infectious complications of rituximab therapy in renal disease

  2017cites this paper
• Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.

  2017cites this paper
• Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders

  2016cites this paper
• Immunization in patients with inflammatory rheumatic diseases.

  2016cites this paper
• Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study.

  2016cites this paper
• Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies

  2016cites this paper
• Prevention of HBV reactivation in patients treated with biologic agents

  2016cites this paper
• Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.

  2016cites this paper
• Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc–positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study

  2016cites this paper
• Rheuma und Infektionen

  2016cites this paper
• Reactivation of Hepatitis B Virus Due to Cancer Chemotherapy and Other Immunosuppressive Drug Therapy

  2016cites this paper
• Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention

  2016cites this paper
• How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease

  2015cites this paper
• Infections in the management of rheumatic diseases: An update.

  2015cites this paper
• Tumor necrosis factor inhibitor therapy for hepatitis B virus–infected individuals: How loud is the alarm bell?

  2015cites this paper
• Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014

  2015cites this paper
• Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

  2015cites this paper